Loading clinical trials...
Loading clinical trials...
Phase II Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-response (REGIMEN-KS HIV)
Conditions
Interventions
CYT107
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
April 8, 2026
Primary Completion Date
January 31, 2036
Completion Date
January 31, 2037
Last Updated
April 13, 2026
NCT06445166
NCT05411237
NCT02595866
NCT05329792
NCT03219671
NCT00020683
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions